Neo-Concept International
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Neo-Concept International Group Holdings Limited, established in 2021 and headquartered in Kwun Tong, Hong Kong, operates as a comprehensive provider of apparel solutions. This subsidiary of Neo-conce...
Latest News
12 days ago · globenewswire.com
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsWATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced presentations at the upcoming the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18-20, 2026, in Barcelona, Spain.
15 days ago · globenewswire.com
Neo-Concept International Announces Share ConsolidationHONG KONG, Nov. 02, 2026 (GLOBE NEWSWIRE) -- On October 29, 2026, Neo-Concept International Group Holdings Ltd (the “Company”) held the Company's Extraordinary General Meeting (the “EGM”) , amongst which a share consolidation (the “Share Consolidation”) was approved by the shareholders, whereby every two (2) to every four hundred (400) issued and unissued shares (namely, both class A ordinary shares of par value US$0.0025 each and class B ordinary shares of par value US$0.0025 each) in the share capital of the Company (the “Range”), with the exact ratio to be set at a specific number within the Range to be determined by the board of directors of the Company in their discretion by not later than the Effective Date (the “Consolidation Ratio”), be consolidated into one (1) share (the “Consolidation Share(s)”), and such Consolidated Share(s) shall have the rights and be subject to the restrictions set out in the Third Amended and Restated Memorandum and Articles of Association of the Company (the “Share Consolidation”). The Share Consolidation was to be effective from such date and time to be determined by the board of directors of the Company which in any event shall not be later than 31 December 2026.
19 days ago · globenewswire.com
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR SymposiumOral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain, on November 18-20, 2026.
20 days ago · globenewswire.com
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR SymposiumAN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd.
21 days ago · globenewswire.com
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.
29 days ago · prnewswire.com
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaTEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
2 months ago · globenewswire.com
Neo-Concept International Group Holdings Ltd Announces Pricing of $2.0 Million Registered Direct OfferingHONGKONG, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Ltd (NASDAQ: NCI) (“Neo-Concept” or the “Company”), a one-stop apparel solution services provider, today announced that it has entered into securities purchase agreements with certain institutional investor for the purchase and sale of 2,000,000 of the Company's Class A ordinary shares (the “Class A ordinary shares”) (or pre-funded warrants in lieu of Class A ordinary shares), at an offering price of $1.00 per share (or $0.99 per pre-funded warrant, which is equal to the per share offering price minus the $0.01 per share exercise price of each pre-funded warrant), in a registered direct offering(the “Offering”).In addition, the purchaser may elect to purchase up to 200% additional Class A ordinary shares and/or pre-funded warrants at the same purchase price within sixty (60) days of the date hereof, subject to certain conditions.
3 months ago · gurufocus.com
ONEOK to Acquire Brazos Midstream's Permian Midland Basin Assets for $4.425 BillionONEOK to Acquire Brazos Midstream's Permian Midland Basin Assets for $4.425 Billion PR Newswire TULSA, Okla., Aug.
3 months ago · gurufocus.com
Woodside Energy Half-Year Report for Period Ended 30 June 2026Woodside Energy Group (ASX: WDS) (NYSE: WDS):This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824
Add to Watchlist
Select watchlists to add or remove NCI